ClinicalTrials.gg
RecruitingNCT06928545Updated Sep 10, 2026

MagDI U.S. Registry

An observational study in Anastomosis, Surgical, Internal Hernia and Bowel Obstruction, sponsored by GT Metabolic Solutions, Inc.. Recruiting at 6 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by GT Metabolic Solutions, Inc. · Observational

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
106
Ages
22 Years and older
Sex
All
01

Study summary

Assess the incidence and severity of internal hernia and bowel obstruction at one year in a U.S. population following use of the MagDI System to create side-to-side duodeno-ileal anastomoses.

Read the detailed description

Small bowel obstruction (SBO) following various abdominal and pelvic surgeries (0.4% - 13.9% at 5 years post-surgery) across obese and non-obese patients has been well studied in the scientific literature and found to be primarily due to intraperitoneal adhesions, with surgical technique (open surgery versus laparoscopic) cited as a key risk factor as reported in a retrospective population-based registry in Sweden (n=108,141). SBO incidence was reported as 3.2% for those undergoing bariatric surgery (n=1,896).

Given the MagDI System premarket clinical study (GTM-001) was conducted outside the U.S., FDA requires one post-market surveillance study to assess and characterize the incidence and severity of internal hernia and bowel obstruction in the U.S. intended use population treated with MagDI System. This study will be conducted through an observational patient registry and compare registry data to the premarket MagDI System clinical study data (GTM-001) and scientific literature. This post-market Registry Study was also a condition of the MagDI System FDA 510(k) clearances K242086 and K243359.

02

Conditions studied

  • Anastomosis, Surgical
  • Internal Hernia
  • Bowel Obstruction

Keywords

  • GT Metabolic
  • MagDI System
  • Magnetic Anastomosis
03

In context

Internal Hernia

8 studies on the registry are indexed under Internal Hernia; 3 are open to participants now.

Browse Internal Hernia studies →

Lead sponsor

GT Metabolic Solutions, Inc. is the lead sponsor of 14 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All eligible patients in the U.S. who undergo a side-to-side duodeno-ileal anastomosis with the MagDI System.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. >21 years of age, at the time of .
  2. (BMI) between 30-50 kg/m2.
  3. Indicated for a side-to-side duodeno-ileal anastomosis and is treated with the MagDI System at a U.S. registry center.
  4. Participant has been informed of the nature of the registry.

Exclusion criteria

Exclusion Criteria:

1. Participant does not provide to be enrolled and followed in the registry.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
106 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • MagDI System

    Participants who underwent the MagDI System procedure and consented to participate in the Registry

    Device: Side-to-side duodenal-ileal anastomosis

Interventions

  • DeviceSide-to-side duodenal-ileal anastomosis

    Side-to-side duodenal-ileal anastomosis formed by magnetic compression using the GT Metabolic MagDI System.

06

What researchers measure

Primary outcomes

  1. Incidence of Internal Hernia and Bowel Obstructions

    To assess and characterize incidence and severity of internal hernia and bowel obstruction at one year in U.S. patients treated with the MagDI System compared with the pre-market study (GTM-001) and scientific literature.

    Time frame: From date of study index procedure through 360 days.

07

Study locations

6 of 6 sites recruiting
  • Ventura Advanced Surgical Associates
    Ventura, California 93003, United States
    Recruiting
    • Hellmuth Billy · Contact805-676-9100
    • Helmuth Billy, MD · Principal investigator
  • HCA Florida Mercy
    Miami, Florida 33133, United States
    Recruiting
  • Baptist Healthcare System, Inc.
    Louisville, Kentucky 40299, United States
    Recruiting
  • Ochsner Clinic Foundation
    Lafayette, Louisiana 70503, United States
    Recruiting
  • Bariatric Specialists of the Carolinas
    Cary, North Carolina 27518, United States
    Recruiting
  • Transform Weight Loss
    Lynnwood, Washington 98036, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06928545
Lead sponsor
GT Metabolic Solutions, Inc.
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Mar 28, 2025
Primary completion
Mar 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Lisa Griffin Vincent, PhD, MA
Contact
clinical@gtmetabolic.com
+1 763-200-1416
Josh Schumacher
Contact
clinical@gtmetabolic.com
+1 763-200-1416

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion